AN-9 (Titan).

Abstract

Titan is developing AN-9 for the potential treatment of various cancers. AN-9 is a histone deacetylase inhibitor analog of butyric acid that causes apoptosis of cancer cells through signaling cellular differentiation. In March 2001, a phase I/II study involving patients with liver tumors was initiated. By November 2001, enrollment had been completed in a second phase II study of refractory non-small-cell lung cancer (NSCLC). In June 2003, Titan began enrollment for a phase IIb trial of AN-9 in combination with docetaxel in patients with NSCLC.

• Authors: Erole Hobdy, John Murren
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 5 Issue 6 Pg. 628-34 (Jun 2004) ISSN: 1472-4472 [Print] England
• PMID: 15242252 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Butyrates
• Drugs, Investigational
• pivalyloxymethyl butyrate

Topics

• Animals
• Antineoplastic Agents (adverse effects, metabolism, pharmacokinetics, therapeutic use)
• Butyrates (adverse effects, metabolism, pharmacokinetics, therapeutic use)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Drugs, Investigational (adverse effects, metabolism, pharmacokinetics, therapeutic use)
• Humans
• Neoplasms (drug therapy)